251 related articles for article (PubMed ID: 24570837)
1. Imaging biomarkers for antiangiogenic therapy in malignant gliomas.
Leu K; Pope WB; Cloughesy TF; Lai A; Nghiemphu PL; Chen W; Liau LM; Ellingson BM
CNS Oncol; 2013 Jan; 2(1):33-47. PubMed ID: 24570837
[TBL] [Abstract][Full Text] [Related]
2. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis and antiangiogenic therapy for malignant gliomas.
Takano S; Kamiyama H; Tsuboi K; Matsumura A
Brain Tumor Pathol; 2004; 21(2):69-73. PubMed ID: 15700836
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response.
Tamura R; Tanaka T; Miyake K; Yoshida K; Sasaki H
Brain Tumor Pathol; 2017 Apr; 34(2):62-77. PubMed ID: 28386777
[TBL] [Abstract][Full Text] [Related]
5. Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients.
Hutterer M; Hattingen E; Palm C; Proescholdt MA; Hau P
Neuro Oncol; 2015 Jun; 17(6):784-800. PubMed ID: 25543124
[TBL] [Abstract][Full Text] [Related]
6. MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.
Jalali S; Chung C; Foltz W; Burrell K; Singh S; Hill R; Zadeh G
Neuro Oncol; 2014 Jun; 16(6):868-79. PubMed ID: 24759636
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas.
Burrell JS; Walker-Samuel S; Baker LC; Boult JK; Jamin Y; Ryan AJ; Waterton JC; Halliday J; Robinson SP
Int J Cancer; 2012 Oct; 131(8):1854-62. PubMed ID: 22290271
[TBL] [Abstract][Full Text] [Related]
9. Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies.
Keunen O; Taxt T; Grüner R; Lund-Johansen M; Tonn JC; Pavlin T; Bjerkvig R; Niclou SP; Thorsen F
Adv Drug Deliv Rev; 2014 Sep; 76():98-115. PubMed ID: 25078721
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic drugs synergize with a membrane macrophage colony-stimulating factor-based tumor vaccine to therapeutically treat rats with an established malignant intracranial glioma.
Jeffes EW; Zhang JG; Hoa N; Petkar A; Delgado C; Chong S; Obenaus A; Sanchez R; Khalaghizadeh S; Khomenko T; Knight BA; Alipanah R; Nguyen TV; Shah C; Vohra S; Zhuang JL; Liu J; Wepsic HT; Jadus MR
J Immunol; 2005 Mar; 174(5):2533-43. PubMed ID: 15728459
[TBL] [Abstract][Full Text] [Related]
11. Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model.
Renner DN; Malo CS; Jin F; Parney IF; Pavelko KD; Johnson AJ
Neurotherapeutics; 2016 Jan; 13(1):226-36. PubMed ID: 26620211
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic Therapy of High-Grade Gliomas.
Jo J; Wen PY
Prog Neurol Surg; 2018; 31():180-199. PubMed ID: 29393186
[TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenic approaches to malignant gliomas.
Soffietti R; Trevisan E; Bertero L; Bosa C; Ruda R
Curr Cancer Drug Targets; 2012 Mar; 12(3):279-88. PubMed ID: 22229250
[TBL] [Abstract][Full Text] [Related]
14. Measurements of tumor vascular leakiness using DCE in brain tumors: clinical applications.
Jain R
NMR Biomed; 2013 Aug; 26(8):1042-9. PubMed ID: 23832526
[TBL] [Abstract][Full Text] [Related]
15. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Wen PY; Macdonald DR; Reardon DA; Cloughesy TF; Sorensen AG; Galanis E; Degroot J; Wick W; Gilbert MR; Lassman AB; Tsien C; Mikkelsen T; Wong ET; Chamberlain MC; Stupp R; Lamborn KR; Vogelbaum MA; van den Bent MJ; Chang SM
J Clin Oncol; 2010 Apr; 28(11):1963-72. PubMed ID: 20231676
[TBL] [Abstract][Full Text] [Related]
16. Post-treatment imaging of gliomas: challenging the existing dogmas.
Bhattacharya K; Rastogi S; Mahajan A
Clin Radiol; 2024 Mar; 79(3):e376-e392. PubMed ID: 38123395
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of the glioma microenvironment].
Herrlinger U; Platten M
Nervenarzt; 2015 Jun; 86(6):684, 686-8, 690-1. PubMed ID: 25962344
[TBL] [Abstract][Full Text] [Related]
18. Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas.
Jansen M; de Witt Hamer PC; Witmer AN; Troost D; van Noorden CJ
Brain Res Brain Res Rev; 2004 Jul; 45(3):143-63. PubMed ID: 15210301
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas.
Argyriou AA; Giannopoulou E; Kalofonos HP
Oncology; 2009; 77(1):1-11. PubMed ID: 19439998
[TBL] [Abstract][Full Text] [Related]
20. Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma.
Ellingson BM; Wen PY; Cloughesy TF
Neuro Oncol; 2018 Mar; 20(4):457-471. PubMed ID: 29040703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
